Valuation

Valuation

Pernod Ricard trades at ~8.8x trailing recurring earnings and a 7.4% flat-dividend yield, a price that embeds roughly 1% long-run growth against a +3% to +6% mid-term guide — the market is discounting the structural reading, and the sell-side's low target of €62.5 essentially equals the €63.88 quote. [1] [2] [3]. The de-rating behind that price is double-sourced: both the multiple and the earnings base fell, and the recovery the company guides to is largely unpriced.

Where the shares trade

Source: closing price €63.88 (3 Jul 2026) and consensus per market data; dividend €4.70 and share count per FY2025 Sales and Results [4].

The building blocks are straightforward. About 252 million shares at €63.88 give a market capitalisation near €16.1bn; adding net debt of €11,168m at 31 December 2025 lifts enterprise value to roughly €27.3bn [5]. Against FY2025 recurring diluted earnings of €7.26 that is 8.8 times trailing profit; against the €5.77 the street expects for FY2026 it is 11.1 times, the higher figure reflecting a further guided decline rather than a richer price [6].

Source: derived from FY2025 recurring earnings [7], recurring profit €2,951m [8], net debt [9] and dividend [10]; market cap and yields at the 3 Jul 2026 price.

Two of these deserve a caveat. The forward multiple looks the most expensive of the set only because FY2026 is the trough the company itself flags — a "transition year" carrying tariffs and a further profit step-down. On the earnings the group has already banked, the shares are nearer 9 times. And the free-cash-flow yield straddles the dividend: reported FCF covers roughly 95% of the payout, the recurring figure a little over 100% (Cash and the Dividend).

A double de-rating

On market price history the stock is down about 29% over one year and roughly 66% over five, and the decline has two independent engines. The multiple compressed — a premium-spirits franchise that historically traded above 20 times earnings now sits below 11 — and the earnings base fell underneath it. Recurring diluted EPS has gone from €7.90 in FY2024 to €7.26 in FY2025, with consensus at €5.77 for FY2026 before a shallow recovery to €5.88 in FY2027 [11]. A shareholder lost on both: less profit, and a lower price for each euro of it.

Sources: FY2024 and FY2025 recurring diluted EPS per FY2025 Sales and Results [12]; FY2026e and FY2027e are consensus estimates.

The de-rating is not Pernod's alone — it has swept the scale players in the category. On dividend yield, the two largest diversified spirits houses now sit at the top of the peer table: Pernod at 7.4% and Diageo at 6.4%, both far above the 2–3% these names historically paid. The premium-and-single-category peers have de-rated less — Brown-Forman yields 3.6%, Rémy Cointreau 1.9%, Campari 1.5%. The market has re-priced the diversified, mature-market-heavy model more harshly than the focused one, which is consistent with the demand and mix problems the report has already traced (Destock or Demand, Pricing Power).

Source: Pernod dividend €4.70 per FY2025 Sales and Results [13]; peer yields per market data, mid-2026.

From yield to implied growth

A 7.4% yield on a dividend the board has held flat is worth translating into a growth expectation. On a constant-growth frame with an 8–9% cost of equity — a fair range for a stable consumer-staples franchise — a starting yield of 7.4% is consistent with roughly 1% long-run growth in the payout. That is well below the +3% to +6% organic net-sales growth the company guides to for FY2027–FY2029 [14]. The gap between the two is the substance of the valuation: at €63.88 the price embeds something close to stagnation, not the recovery management describes.

That framing carries its own qualifier. The same low-single-digit implied growth is what makes the yield fragile rather than generous — a genuinely structural downshift would pressure the very payout that anchors the price, since reported free cash flow already covers the dividend only marginally (Cash and the Dividend). A 7.4% yield is a floor only for as long as the dividend holds.

The range and the two scenarios

The cyclical and structural readings imply very different earnings paths, and the sell-side's own target range spans both.

Source: derived from consensus recurring EPS and FY2023–FY2025 reported recurring earnings [15]; scenario multiples are illustrative.

The arithmetic is deliberately simple, and it lands close to where analysts actually sit. The consensus mean target of about €87 is roughly FY2024-level recurring earnings at today's multiple — a partial-recovery bet with no re-rating required. The street high near €122 needs both: earnings back toward the FY2023 peak and a multiple closer to a normal staples 14 times. And the street low, at €62.5, is essentially the current price — the structural view, in which the FY2026 trough is the new base. That the low target and the market price coincide is the clearest sign that the price is discounting the pessimistic reading.

Source: 12-month price targets and current price per consensus market data (19 analysts), as of 3 Jul 2026.

The dispersion itself is informative. With a low of €62.5 and a high of €122, the sell-side has an unusually wide spread — a near-doubling between the most and least optimistic — which is what genuine disagreement over cyclical-versus-structural looks like in a target table. The balance of opinion is cautious rather than bullish: eight buy ratings against ten holds and one sell, and estimate revisions have run against the stock, with the large majority of FY2027 EPS changes in the past month cut rather than raised.

My read, offered once: at roughly 9 times the earnings it has already banked and a 7.4% yield, the price is discounting close to the structural end of the through-line — little of the guided recovery is in the number, which is where the asymmetry sits if the decline proves cyclical. The strongest fact against treating that as an opportunity is that estimates are still falling and the dividend underpinning the yield is only thinly covered, so a structural downshift would erode the floor rather than pay you to wait.

What would change the read

The price moves on the same evidence the rest of the report has weighed. A turn up in US category sell-out that ends the distributor destock (Destock or Demand), a resolution of the China cognac and EU-brandy duties that restores Martell's earnings, EPS revisions that stop falling, or deleveraging back below 3x net-debt/EBITDA — any of these would pull the implied path away from stagnation. Absent them, the 8.8-times multiple and the 7.4% yield are the market's price for a business it currently expects to hold, not to grow.